PriceTracker GLP-1
Loading the index…

Try

Find the cheapest for me
Loading the index…

Try

GLP-1 TV · Clinician

Do GLP-1 Agonists Cause Thyroid Cancer? (Wegovy, Ozempic, Saxenda, Victoza)

Clinician6:07May 2023

Today’s cheapest semaglutide$39/mo at Wellmedr, sale price.Compare all semaglutide prices Price read 22 Nov 2026 from the seller’s own page, ranked by price alone. That price is a compounded drug, and compounded drugs are not FDA-approved. Not from the video’s creator.

Our summary

According to the video, the speaker explains that GLP-1 agonists such as Wegovy, Ozempic, Saxenda, Victoza and Trulicity were first designed to treat diabetes and were later found to cause substantial weight loss. He says he has recommended them and seen good results, but that a medication is not worth taking if its side effects outweigh its benefits.

Published by Dr. Westin Childs on YouTube

As published by the channel. Not medical advice, and not an endorsement.

What else the video covers

He says both animal and human studies suggest a link between long-term use of these drugs and thyroid cancer. He adds that thyroid removal, the treatment for thyroid cancer, would almost certainly cause weight gain, which is the opposite of what people on these drugs want. He cites a French study that, in his description, found an increased risk of thyroid cancer overall and of a rare type called medullary thyroid cancer after one to three years of use. He reports about 2,500 cases among 3.7 million people, which he puts at 0.7 percent, and says such low numbers can make it easy to create a connection where none exists.

The speaker says he would still prefer people avoid the drugs if possible. If someone does use one, he suggests keeping it under about one year, and argues that not losing weight may raise cancer risk more than the drugs do, noting that at least 13 cancers are linked to obesity. He then lists alternatives: a whole food diet, a fasting routine, resistance training with a high protein diet, and bioidentical T3 thyroid hormone or testosterone replacement therapy. He says a GLP-1 agonist should be a last resort, used briefly until the target weight is reached, or the weight will return.

Our summary of what is said, in our words. Doses, results and prices are the speaker’s, not advice.

Takeaways

The main points, in the order they come up. Tap a time to play from there.

  1. 0:32 The speaker says he has seen good results in patients on GLP-1 agonists but that side effects must not outweigh the benefits.
  2. 1:02 He says animal and human studies suggest a link between long-term use and thyroid cancer, and that thyroid removal would likely cause weight gain.
  3. 1:33 He describes a French study finding increased thyroid cancer risk after one to three years, with about 2,500 cases among 3.7 million people.
  4. 3:04 He recommends using a GLP-1 agonist for less than one year if at all, and argues that obesity-linked cancer risk is also worth weighing.
  5. 4:05 He suggests a whole food diet, fasting, exercise and bioidentical thyroid hormones or testosterone before turning to a GLP-1 agonist.
  6. 5:36 He says a GLP-1 agonist should be a last step, used briefly until the target weight is reached, or the weight will come back.

Key moments

Tap one to play from there.

  1. 0:00 Intro
  2. 0:56 Whats the big deal
  3. 2:21 Should you take them
  4. 3:42 Should you lose weight

What the video says

As stated in the video, not checked by us. Doses and results are the speaker’s, not advice.

Medication
Ozempic and Wegovy

Questions this video answers

Do GLP-1 agonists cause thyroid cancer?

According to the video, animal and human studies suggest a link between long-term use and thyroid cancer. The speaker cites a French study that found increased risk after one to three years, but he also says the absolute numbers are small and that low numbers can make a connection look real when there is none.

How many people got thyroid cancer in the French GLP-1 study?

The speaker says the study found about 2,500 cases of thyroid cancer among 3.7 million people, which he describes as 0.7 percent. He notes this is a small share of the total but still matters to those affected.

How long should you take a GLP-1 agonist to limit thyroid cancer risk?

The speaker says that if someone uses one, he recommends a short period, preferably less than one year, because the risk in the studies appeared tied to long-term use. He adds that the drug should be used only until the target weight is reached.

What does the speaker suggest trying before a GLP-1 agonist?

He suggests a whole food diet of any type, a fasting routine, regular exercise with a high protein diet and resistance training, and possibly bioidentical T3 thyroid hormone or testosterone replacement therapy. He says he considers these preferable to a GLP-1 agonist.

Videos on the same question

The closest videos in the library by what is said in them, not by title.

Read next

Our guides closest to what this video covers, with prices checked weekly.

  • What is GLP-1? The hormone, how the drugs work, and every GLP-1 medication on the market

    GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases after you eat. It tells the pancreas to release insulin when blood sugar is high, holds back glucagon, slows how fast the stomach empties, and acts on the parts of the brain that regulate appetite. GLP-1 drugs copy that hormone but last far longer: a week for the injections, a day for the pills. Seven brands are on the US market, from Ozempic and Mounjaro for type 2 diabetes to Wegovy, Zepbound and Foundayo for weight loss.

  • GLP-1 vs GLP-2 vs GLP-3: what the names mean, and which ones you can actually buy

    GLP-1 drugs such as semaglutide act on one receptor. "GLP-2" is used online for tirzepatide (Zepbound, Mounjaro), which acts on two, GIP and GLP-1, and "GLP-3" for retatrutide, which adds the glucagon receptor. Neither nickname is the real name: GLP-2 is a separate gut hormone whose drug, Gattex, treats short bowel syndrome. Retatrutide produced 28.3% mean weight loss at 80 weeks in its phase 3 trial but is not FDA-approved; Lilly plans to file in Q1 2027. Tirzepatide is the strongest option you can buy today.

  • GLP-1s for binge eating: what semaglutide, liraglutide and tirzepatide trials show

    No GLP-1 is FDA approved for binge eating disorder; the only approved drug is lisdexamfetamine (Vyvanse). A 2026 meta-analysis of 25 randomized trials reports moderate drops in binge eating on GLP-1s, larger in people diagnosed with the disorder, but rates every trial at high risk or some concerns of bias. The one placebo-controlled liraglutide trial in diagnosed BED showed no significant difference. A tirzepatide versus Vyvanse trial is recruiting.

Next steps

Ozempic prices

Insurance

Find more like it

Side effectsWeigh-in and resultsExercise and strengthHow it worksThe trials

Up next

More from this collection

Watched it? See what it costs.

Every GLP-1 program we track, ranked by what actually leaves your account.

Back to GLP-1 TV